• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Catalyst Pharmaceuticals Set to Join S&P SmallCap 600

    9/12/22 7:30:00 PM ET
    $CG
    $CPRX
    $MANT
    $SPGI
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CG alert in real time by email

    NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Catalyst Pharmaceuticals Inc. (NASD: CPRX) will replace Mantech International Corp. (NASD: MANT) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, September 15. The Carlyle Group Inc. (NASD: CG) is acquiring ManTech International in a transaction expected to be completed soon pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    September 15, 2022

    S&P SmallCap 600

    Addition

    Catalyst Pharmaceuticals

    CPRX

    Health Care





    Deletion

    Mantech International

    MANT

    Industrials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/catalyst-pharmaceuticals-set-to-join-sp-smallcap-600-301622481.html

    SOURCE S&P Dow Jones Indices

    Get the next $CG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CG
    $CPRX
    $MANT
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    The Carlyle Group Inc.
    $CG
    7/10/2025$65.00Neutral → Buy
    Citigroup
    The Carlyle Group Inc.
    $CG
    5/14/2025$56.00Hold → Buy
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    The Carlyle Group Inc.
    $CG
    3/19/2025Outperform → Perform
    Oppenheimer
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Catalyst Pharmaceuticals Inc.
    $CPRX
    2/4/2025$28.00Outperform
    Robert W. Baird
    The Carlyle Group Inc.
    $CG
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    S&P Global Inc.
    $SPGI
    12/20/2024$600.00Buy
    Citigroup
    More analyst ratings

    $CG
    $CPRX
    $MANT
    $SPGI
    SEC Filings

    View All

    SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

    144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    8/26/25 10:46:36 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

    8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    8/25/25 4:30:16 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form N-PX filed by The Carlyle Group Inc.

    N-PX - Carlyle Group Inc. (0001527166) (Filer)

    8/22/25 4:41:19 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, S&P Global Mobility Eager William W

    4 - S&P Global Inc. (0000064040) (Issuer)

    8/19/25 4:05:15 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    New insider Eager William W claimed ownership of 6,202 shares (SEC Form 3)

    3 - S&P Global Inc. (0000064040) (Issuer)

    8/19/25 4:00:37 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    General Counsel Ferguson Jeffrey W. sold $19,088,342 worth of shares (300,000 units at $63.63), decreasing direct ownership by 28% to 753,255 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    8/13/25 5:12:16 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carlyle Group upgraded by Citigroup with a new price target

    Citigroup upgraded Carlyle Group from Neutral to Buy and set a new price target of $65.00

    7/10/25 8:23:02 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Group upgraded by TD Cowen with a new price target

    TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

    5/14/25 8:48:54 AM ET
    $CG
    Investment Managers
    Finance

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

    4/10/25 8:19:38 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

    CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Lupin Ltd and Lupin Pharmaceuticals, Inc. (collectively, "Lupin"). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Lupin's Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version of FIRDA

    8/26/25 7:12:43 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    S&P Cotality Case-Shiller Index Records Annual Gain in June 2025

    The U.S. National Index, the 20-City Composite, and the 10-City Composite continue to display growth with 1.9%, 2.1% and 2.6%, respectively.Housing wealth erodes in real terms for second consecutive month, with home price gains of 1.9% trailing consumer inflation of 2.7%.Regional leadership flips as New York (7.0%) and Chicago (6.1%) outpace former pandemic darlings Tampa (-2.4%) and Phoenix (-0.1%).NEW YORK, Aug. 26, 2025 /PRNewswire/ -- S&P Dow Jones Indices (S&P DJI) today released the June 2025 results for the S&P Cotality Case-Shiller Indices, formerly known as the S&P CoreLogic Case-Shiller Indices.  More than 27 years of history are available for the data series and can be accessed i

    8/26/25 11:46:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Interactive Brokers Group Set to Join S&P 500, Talen Energy to Join S&P MidCap 400 and Kinetik Holdings to Join S&P SmallCap 600

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Group Inc. (NASD: IBKR) will replace Walgreens Boots Alliance Inc. (NASD: WBA) in the S&P 500, and Talen Energy Corp. (NASD: TLN) will replace Interactive Brokers Group in the S&P MidCap 400 effective prior to the opening of trading on Thursday, August 28. Sycamore Partners is acquiring Walgreens Boots Alliance in a deal expected to be completed soon, pending final closing conditions.  Kinetik Holdings Inc. (NYSE:KNTK) will replace Pacific Premier Bancorp Inc. (NASD: PPBI) in the S&P SmallCap 600 ef

    8/25/25 5:41:00 PM ET
    $COLB
    $IBKR
    $KNTK
    Savings Institutions
    Finance
    Investment Bankers/Brokers/Service
    Natural Gas Distribution

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Financials

    Live finance-specific insights

    View All

    Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

    Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product Revenue of $84.8 Million, Up 9.7% YoY; First Half 2025 Net Product Revenue of $168.6 Million, a 16.9% Increase Over Prior Year, Underscoring Sustained Momentum and Confidence in Long-Term Growth AGAMREE® Q2 2025 Net Product Revenue of $27.4 Million, Up 212.9% YoY; First Ha

    8/6/25 4:13:09 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Carlyle Secured Lending, Inc. Announces Financial Results For Second Quarter Ended June 30, 2025, Declares Third Quarter 2025 Dividend of $0.40 Per Common Share

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its second quarter ended June 30, 2025. Justin Plouffe, CGBD's Chief Executive Officer, said, "Despite market uncertainty, the second quarter was another record quarter of originations for both CGBD and the broader Carlyle Direct Lending platform. With CGBD net financial leverage at the mid-point of our target range, we remain well positioned to benefit from the expected pickup in deal volume in the second half of the year. Although spreads in the overall market remain hist

    8/5/25 4:01:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    CommScope to Sell its Connectivity and Cable Solutions Segment to Amphenol Corporation for $10.5 billion

    CommScope (NASDAQ:COMM), a global leader in network connectivity, announced today it has entered into a definitive agreement to sell its Connectivity and Cable Solutions (CCS) segment to Amphenol Corporation (NYSE:APH). CommScope (the "Company") is selling its CCS business to Amphenol for approximately USD $10.5 billion in cash, to be paid by Amphenol upon closing. The sale is expected to close within the first half of 2026, subject to customary closing conditions, including receipt of applicable regulatory approvals and the affirmative vote of the shareholders. The vote is required under Delaware law due to the nature and size of the transaction. The Company expects net proceeds after

    8/4/25 7:00:00 AM ET
    $APH
    $CG
    $COMM
    Electrical Products
    Technology
    Investment Managers
    Finance

    $CG
    $CPRX
    $MANT
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    11/14/24 9:55:56 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/21/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance